References
- Abrams S. M. L., Pierce D. M., Johnston A., Hedges A., Franklin R. A., Turner P. Pharmacokinetic and pharmacodynamic interactions between indoramin and ethanol. Human Toxicology 1989; 8: 237–241
- Archibald J. L. Some recent developments in the pharmacology and pharmacokinetics of indoramin. Journal of Cardiovascular Pharmacology 1986; 8: S16
- Draffan G. H., Clare R. A., Williams F. W., Emons E., Jackson J. L. Applications of gas chromatography-mass spectrometry in quantitative drug and metabolite measurement. Mass Spectrometry in Biochemistry and Medicine, A. Frigerio, N. Castagnoli. Raven Press, New York 1974; 8–17
- Draffan G. H., Lewis P. J., Firmin J. L., Jordan T. W., Dollery C. T. Pharmacokinetics of indoramin in man. British Journal of Clinical Pharmacology 1976; 3: 489–495
- Franklin R. A., Pierce D. M. Studies on the biotransformation of indoramin in the patas monkey. Xenobiotica 1981; 11: 755–762
- Franklin R. A., Robson P., Stevenson D. Studies on the metabolism of the new antihypertensive agent, indoramin, in man. European Journal of Clinical Pharmacology 1983; 24: 629–634
- Holmes B., Sorkin E. M. Indoramin: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in hypertension and related vascular, cardiovascular and airway diseases. Drugs 1986; 31: 467–499
- Iacovou J. W., Dunn M. Indoramin—an effective new drug in the management of bladder outflow obstruction. British Journal of Urology 1987; 60: 526–528
- Idle J. R., Smith R. L. Polymorphism of oxidation at carbon centers of drugs and their clinical significance. Drug Metabolism Reviews 1979; 9: 301–317
- Johnson E. S. Indoramin in essential hypertension. British Journal of Clinical Pharmacology 1981; 12: 401–404
- Neumann G., Wilke G., Reimold W. V., Pierce D. M., Geising M. Pharmacokinetics of indoramin and its metabolite 6-hydroxyindoramin after single and multiple doses to cirrhotic liver patients. Journal of Cardiovascular Pharmacology 1986; 8: S20
- Norbury H. M., Franklin R. A., Marrott P. K., Warrington S. J. Pharmacokinetics of intravenous indoramin in middle-aged male and female volunteers. European Journal of Clinical Pharmacology 1983; 25: 243–246
- Norbury H. M., Franklin R. A., Marrott P. K., Warrington S. J. Pharmacokinetics of oral indoramin in elderly and middle-aged male and female volunteers. European Journal of Clinical Pharmacology 1984; 27: 247–249
- Pierce D. M., Abrams S. M. L., Franklin R. A. Pharmacokinetics and systemic availability of the antihypertensive agent indoramin and its metabolite 6-hydroxyindoramin in healthy subjects. European Journal of Clinical Pharmacology 1987 a; 32: 619–623
- Pierce D. M., Smith S. E., Franklin R. A. The pharmacokinetics of indoramin and 6-hydroxyindoramin in poor and extensive hydroxylators of debrisoquine. European Journal of Clinical Pharmacology 1987 b; 33: 59–65
- Pierce D. M., Abrams S. M. L., Franklin R. A. Intra- and inter-subject variation in the pharmacokinetics of indoramin and its 6-hydroxylated metabolite. European Journal of Clinical Pharmacology 1988 a; 35: 195–198
- Pierce D. M., Warrington S. M. L., Franklin R. A. Pharmacokinetics of indoramin and its 6-hydroxylated metabolite after repeated oral dosing. Biopharmaceutics and Drug Disposition 1988 b; 9: 147–157
- Swaisland A. J. Determination of therapeutic concentrations of indoramin by liquid chromatography with fluorimetric detection. Analyst 1981; 106: 717–719
- Volans G. N., Jeffereys D., Latham A. N., Frost T. Pharmacokinetics of oral indoramin. Current Medical Research and Opinion 1982; 8: 51–53